Yuhan Corp. to market Nippon Shinyaku's prulifloxacin in Korea

Yuhan Corp. announced on February 17 that it signed a licensing agreement with Japanese drug market Nippon Shinyaku for the long-term exclusive marketing of oral quinolone antibiotic prulifloxacin in Korea..

Yuhan Corp. said that prulifloxacin is an innovative drug as a prodrug type for the first time in the world and its metabolized substance has a broad spectrum of antimicrobial activity a...